Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

In the 132-patient ROCKstar study, almost three quarters of chronic GVHD patients treated with a daily oral dose of belumosudil (KD025) saw an improvement in symptoms that lasted for at least six ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Mesoblast Limited's Remestemcel-L has been approved for treating acute graft-versus-host disease, driving recent share price momentum and a potential market cap of $2 billion. The company is ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

It's a lost opportunity to promote a healthy gut microbiome, recover from treatment-related microbiota injury, and protect against GVHD," said first author Jenny Paredes, PhD, a staff scientist at ...

The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.

The researchers found that itacitinib resulted in low CRS grades; 22%, 78%, and 0% of patients had grades 0, 1, and 2 to 5, respectively. (HealthDay News) — For patients with haploidentical ...